Skip to main content

Table 1 Cohort demographics and plasma biomarker values

From: A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis

  Cohort 1 (N = 37) Cohort 2 (N = 94) Cohort 3 (N = 121) Cohort 4 (N = 26) Cohort 5 (N = 96) Cohort 6 (N = 40) All Cohorts (N = 414)
Age
 Mean (SD) 73.1 (7.8) 71.1 (8.0) 66.1 (7.8) 75.1 (6.8) 71.4 (7.6) 69.7 (9.1) 70.0 (8.3)
 Min 59.2 56.7 47.0 66.1 45.0 46.1 45.0
 Max 87.5 93.1 85.0 88.9 89.0 86.0 93.1
Sex
 Male (%) 54.1% 58.5% 23.1% 57.7% 40.6% 35% 41.3%
Amyloid Positive (%) 49% 46% 17% 42% 49% 52% 39%
CDR
 Percent CDR = 0 [N] - [0] 50% [94] - [0] 56% [25] - [0] 75% [40] 57.2% [159]
MMSE
 Percent MMSE = 27–30 [N] 45.9% [37] - [0] 100% [121] 64% [25] - [0] 85% [40] 84.3% [223]
Biomarker Used to Determine Brain Amyloid Status (% participants)
 PiB 68% 54% 52% 28%
 Amyvid 32% 22% 48% 19%
 Neuraceq 78% 18%
 CSF ELISA 100% 23%
 CSF IPMS 100% 46% 12%
ApoE Proteotype
 E2/E3 (%) 5.4% 8.5% 5.0% 23.1% 7.3% 7.5% 7.7%
 E2/E4 (%) 2.7% 6.4% 2.1% 5.0% 2.7%
 E3/E3 (%) 51.4% 46.8% 47.9% 46.2% 52.1% 45.0% 48.6%
 E3/E4 (%) 29.7% 28.7% 29.8% 19.2% 34.4% 35.0% 30.4%
 E4/E4 (%) 10.8% 9.6% 17.4% 11.5% 4.2% 7.5% 10.6%
C2N Plasma Aβ42/40
 Mean (SD) 0.089 (0.012) 0.102 (0.010) 0.101 (0.009) 0.096 (0.009) 0.087 (0.009) 0.100 (0.009) 0.097 (0.011)
 Min 0.065 0.084 0.080 0.082 0.059 0.080 0.059
 Max 0.113 0.148 0.126 0.114 0.113 0.117 0.148
  1. No patients had the E2/E2 genotype. Cohort 2 used Heparin tubes whereas all other cohorts used EDTA tubes for blood collection. [N] is the number of participants where data was available/provided
  2. CSF cerebrospinal fluid, ELISA enzyme-linked immunoassay, IPMS immunoprecipitation-mass spectrometry, CDR Clinical Dementia Rating, MMSE Mini-Mental State examination